Navigating the Diagnosis and Management of Heart Failure in Women: Identifying and Understanding the Gaps to Improve Outcomes

This activity is jointly provided by Global Education Group and Cardiometabolic Health Congress.

This activity is supported by an educational grant from Merck Sharp & Dohme LLC.

Program Overview:

Release Date: April 3, 2023
Expiration Date: May 24, 2024

The prevalence of heart failure (HF) is greater in women compared to men; however, significant gaps exist in the management of women with heart failure. Compared to men, women with HF receive suboptimal guideline-directed medical therapy (GDMT), and despite a higher HF symptom burden, they are frequently misdiagnosed and also underrepresented in HF clinical trials, which further exacerbates these gaps. In recent years, significant advances in the prevention and treatment of HF have been made, all with the potential to alter treatment paradigms now and in the future. In this activity, experts will review these gaps, as well as discuss how to apply the recent advances to improve the care of women with HF.

The design of this activity ensures that these topics are presented in a format that is easy to follow, containing a mix of videos & resources, organized into different segments to facilitate learning.

---

Learning Objectives:

After completing this activity, the participant should be better able to:

• Discuss the burden of HF in women, as well as differences in HF etiology and risk factors.
• Recognize the differences in HF symptom presentation in women in order to identify HF in a timely manner.
• Summarize important differences and considerations for the application of GDMT in women with HF.
• Develop treatment options for women with HFrEF or HFpEF according to guidelines, patient-specific risk factors, and efficacy and safety of available therapies.

---

Target Audience

US-based healthcare professionals, including cardiologists, endocrinologists, lipidologists, primary care clinicians (PCPs), sleep specialists, registered nurses, advanced practice registered nurses, dieticians, pharmacists, and other allied health professionals involved in the management and treatment of cardiometabolic patients.

---

Alanna A. Morris, MD, MSc
Associate Professor of Medicine, Emory University School of Medicine
Atlanta, GA

Dr. Morris discloses the following:

• Consulting Fee (e.g., Advisory Board): Abbott, Acorai, BI Lilly, Cytokinetics, Edwards LifeSciences, Ionis, Merck, Regeneron
• Contract Research: Merck, Myokardia
• Honoraria: Abbott, Acorai, BI Lilly, Cytokinetics, Edwards LifeSciences, Ionis, Merck, Regeneron

Ileana L. Piña, MD, MPH
Professor of Medicine, Thomas Jefferson University
Cleveland Heights, OH

Dr. Piña has nothing to disclose.

---

JOINT PROVIDERSHIP STATEMENT

This activity is jointly provided by Global Education Group and Cardiometabolic Health Congress.

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and Cardiometabolic Health Congress. Global is accredited by the ACCME to provide continuing medical education for physicians

PHYSICIAN CREDIT DESIGNATION

Global Education Group designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ABIM MOC

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

NURSING CONTINUING EDUCATION

Global Education Group is accredited with distinction as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation.

This educational activity for 1.0 contact hours is provided by Global Education Group. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

PHARMACY CONTINUING EDUCATION

Global Education Group (Global) designates this continuing education activity for 1.0 contact hour(s) (0.10 CEUs) of the Accreditation Council for Pharmacy Education.

Universal Activity Number (UAN): 0530-9999-22-243-H01-P.
Type of activity: Knowledge

For Pharmacists: Upon completing the post-test and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 – 6 weeks.

DIETITIAN ACCREDITATION STATEMENT

Global Education Group is a Continuing Professional Education (CPE) Accredited Provider with the Commission on Dietetic Registration (CDR). CDR Credentialed Practitioners will receive 1 Continuing Professional Education units (CPEUs) for completion of this activities / materials. CPE Provider #GE012

---

INSTRUCTIONS FOR PARTICIPATION

This activity is complimentary and available during the period April 3, 2023 through April 3, 2024. Participants must read the learning objectives and faculty disclosures, study the educational activity, obtain a score of 70% or better on the post-test, and complete the evaluation. Upon completing, your certificate will be available for print.

For questions about the accreditation of this activity, please contact Global at 303-395-1782 or cme@globaleducationgroup.com.

For Pharmacists: Please complete the evaluation instructions above. Upon registering and completing the activity evaluation, your transcript information will be sent to the NABP CPE Monitor Service within 4-6 weeks.

---

DISCLOSURES

Global Education Group (Global) adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Global are required to disclose all financial relationships with any ineligible company within the past 24 months to Global. All financial relationships reported are identified as relevant and mitigated by Global in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Global to assure objectivity and that the activity is free of commercial bias.

All relevant financial relationships have been mitigated.

The planners and managers have the following relevant financial relationships with ineligible companies:

Name of Planner or Manager	Reported Financial Relationship
Rhys Williams, MSN, FNP-C, RN	Nothing to disclose.
Lauren Sinclair	Nothing to disclose.
Lindsay Borvansky	Nothing to disclose.
Liddy Knight	Nothing to disclose.
Andrea Funk	Nothing to disclose.
Ashley Cann	Nothing to disclose.
Deborah Sharkey	Nothing to disclose.
Amanda Turner	Nothing to disclose.
Kelly Pechous	Nothing to disclose.
Karin McAdams	Nothing to disclose.
Shpetim Karandrea, PhD	Nothing to disclose.
Neha Agarwal, PhD	Nothing to disclose.

DISCLOSURE OF UNLABELED USE

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) and Cardiometabolic Health Congress do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLAIMER

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.